The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Byungho LimDabin YooYounghwa ChunAreum GoKyung-Jin ChoDaeun ChoiMyoung Eun JungHa Young LeeRebecca J BoohakerJin Soo LeeDooYoung JungGildon ChoiPublished in: Blood cancer journal (2022)